Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 5—May 2013


Treatment of Tularemia in Patient with Chronic Graft-versus-Host Disease

Jan WeileComments to Author , Erik Seibold, Cornelius Knabbe, Martin Kaufmann, and Wolf Splettstoesser
Author affiliations: Heart and Diabetes Centre North Rhine–Westphalia, Bad Oeynhausen, Germany (J. Weile, C. Knabbe); Bundeswehr Institute of Microbiology, Munich, Germany (E. Seibold, W. Splettstoesser); University of Rostock, Rostock, Germany (W. Splettstoesser); Robert-Bosch-Hospital, Stuttgart, Germany (M. Kaufmann)

Main Article


Susceptibility testing of the blood culture isolate (Francisella tularensis subsp. holarctica) break point analysis according to CLSI standard*

Antimicrobial agent MIC, mg/L Interpretation
Tetracycline 1.0 S
Ciprofloxacin 0.125 S
Levofloxacin 0.25 S
Chloramphenicol 2 S
Gentamicin 0.5 S
Streptomycin 2 S

*CLSI, Clinical and Laboratory Standards Institute; S, susceptible; R, resistant.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO